Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine OVERALL - PROJECT SUMMARY This is the 3nd CCSG competitive renewal application of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine (BCM) in Houston, Texas. Houston is the 4th largest city in the United States with a very diverse population and Harris County is one of the most rapidly growing in the country. The DLDCCC Catchment Area has expanded from the core of Harris county to include the 8 surrounding counties which comprise the Houston Metropolitan Statistical Area (MSA), representing a diverse population of more than 7 million individuals (this population is greater than 35 states). The DLDCCC is a matrix center with BCM as the lead partner with 4 hospital affiliates, Texas Children?s, the DeBakey Veterans Affairs Medical Center, Ben Taub Hospital, and the new Baylor St. Luke?s Medical Center as formal affiliates. The DLDCCC received NCI designation in 2007 and comprehensive designation in 2014 and through our evaluation and planning process and recommendations from our EAC and internal committees, we have since made significant progress strengthening our scientific programs. 53 new cancer faculty have been recruited to the DLDCCC which now has 192 Research members, 78 Clinical members and 18 Adjunct members. Our cancer-relevant peer reviewed research funding now exceeds $169 million, with more than $49 million ($34M direct) coming from the NCI. Several important scientific accomplishments have been made that have an impact in our Catchment Area and globally. The DLDCCC comprises 7 research programs: Cell Signaling and Metabolism, Mechanism of Cancer Evolution, Nuclear Receptor, Transcription and Chromatin Biology, Breast Cancer, Cancer Cell and Gene Therapy, Cancer Prevention and Population Science, and Pediatric Cancer. Significant investments have strengthened the 10 Shared Resources, which offer leading technologies. A new shared resource in Advanced In Vivo Cancer Models further enhances our capabilities. The Clinical Protocol and Data Management Core has been significantly enhanced and accruals to clinical trials have increased. Accrual of racial and ethnic minorities is outstanding. The Office of Outreach and Health Disparities which drives COE disseminates new information and services to the community, especially the underserved. Training and education have been integrated into our Programs through the CRCE core. In this renewal, we ask for increased funding for our 10 Shared Resources and other expanded activities important to our mission and goals.

Public Health Relevance

Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine OVERALL - PROJECT NARRATIVE Cancer is a leading cause of morbidity and mortality in the United States and globally. The diagnosis and treatment of cancer are extraordinarily demanding and increasingly expensive with major impacts on our economy. Although overall survival from cancer has improved and certain cancers can be prevented or cured, much remains to be accomplished to improve patient outcome through research to develop novel strategies to prevent, diagnose early, and effectively treat this disease. The Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine has put together a strong multidisciplinary team of scientists, clinicians, educators, and community outreach experts to further improve survival from cancer both in our Catchment Area and globally, and to educate the scientists and clinicians of the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA125123-14
Application #
10025004
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2007-07-01
Project End
2025-06-30
Budget Start
2020-08-14
Budget End
2021-06-30
Support Year
14
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
De Maio, Antonia; Yalamanchili, Hari Krishna; Adamski, Carolyn J et al. (2018) RBM17 Interacts with U2SURP and CHERP to Regulate Expression and Splicing of RNA-Processing Proteins. Cell Rep 25:726-736.e7
Singh, Sunita; Jangid, Rahul K; Crowder, Alyssa et al. (2018) Foxi3 transcription factor activity is mediated by a C-terminal transactivation domain and regulated by the Protein Phosphatase 2A (PP2A) complex. Sci Rep 8:17249
Lulla, Premal D; Hill, LaQuisa C; Ramos, Carlos A et al. (2018) The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol 16:375-386
Reineke, Lucas C; Cheema, Shebna A; Dubrulle, Julien et al. (2018) Chronic starvation induces noncanonical pro-death stress granules. J Cell Sci 131:
Bayrer, James R; Wang, Hongtao; Nattiv, Roy et al. (2018) LRH-1 mitigates intestinal inflammatory disease by maintaining epithelial homeostasis and cell survival. Nat Commun 9:4055
Charendoff, ChloƩ I; Bouchier-Hayes, Lisa (2018) Lighting Up the Pathways to Caspase Activation Using Bimolecular Fluorescence Complementation. J Vis Exp :
Cardona, Sandra M; Kim, Sangwon V; Church, Kaira A et al. (2018) Role of the Fractalkine Receptor in CNS Autoimmune Inflammation: New Approach Utilizing a Mouse Model Expressing the Human CX3CR1I249/M280 Variant. Front Cell Neurosci 12:365
Zhang, Manqi; Suarez, Egla; Vasquez, Judy L et al. (2018) Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene :
Chiang, Yun-Chen; Park, In-Young; Terzo, Esteban A et al. (2018) SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma. Cancer Res 78:3135-3146
Choi, Byung-Kwon; Dayaram, Tajhal; Parikh, Neha et al. (2018) Literature-based automated discovery of tumor suppressor p53 phosphorylation and inhibition by NEK2. Proc Natl Acad Sci U S A 115:10666-10671

Showing the most recent 10 out of 991 publications